The goal of this study was to investigate the biomarkers, neurofilament light chain, inflammatory markers, calcitonin-gene-related peptide, and metabolites from the kynurenine pathway in patients with severe post-concussive symptoms. The main question it aimed to answer was: * Are the biomarker concentrations significantly changed in patients with severe post-concussive symptoms compared to healthy individuals? * Do the biomarker concentrations change at follow-up? Participants were recruited from a recently published randomized controlled trial (Clinicaltrials.gov no. NCT02337101 / PMID: 31891145 ). The biomarker concentrations were compared to a healthy control group recruited from the Blood Bank at Aarhus University Hospital in 2022.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Neurofilament light chain at baseline (primary outcome)
Timeframe: The baseline blood sample was taken up to 7 months after the concussion (4 months median).
Neurofilament light chain at follow-up (primary outcome)
Timeframe: The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample.
Self-reported post-concussion symptoms score (primary outcome)
Timeframe: The baseline symptom score (RPQ) was obtained from the patients up to 7 months after the concussion (4 months median), and the follow-up score was obtained up to 16 months (10.5 median) after the concussion
Calcitonin-gene related peptide at baseline (CGRP)
Timeframe: The baseline blood sample was taken up to 7 months after the concussion (4 months median).
Calcitonin-gene related peptide at follow-up (CGRP)
Timeframe: The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample.